Navigation Links
Anti-angiogenic drugs impede chemotherapy-stimulated tumor recovery
Date:9/8/2008

Scientists have gained new insight into a mechanism whereby chemotherapy may actually assist the rapid regrowth of tumors after treatment. The research, published by Cell Press in the September issue of the journal Cancer Cell, also helps to explain why a combination of traditional chemotherapy with drugs that block formation of new blood vessels might impede the devastating tumor recovery that often follows cancer therapy.

"Chemotherapy remains the most commonly employed form of systemic cancer treatment. However, although partial or complete shrinkage of tumor mass is frequently induced in chemotherapy-responsive tumors, survival benefits of such responses can be compromised by rapid regrowth of the drug-treated tumors," says senior study author Dr. Robert S. Kerbel from the University of Toronto.

Clinical trials have indicated that drugs that inhibit the growth of blood vessels, called antiangiogenic drugs, can sometimes enhance the effectiveness of traditional chemotherapy. For example, coadministration of the antiangiogenic drug bevacizumab with the chemotherapeutic agent paclitaxel improves survival benefits for metastatic breast cancer and small cell lung cancer. In contrast, coadministration of bevacizumab with gemcitabine for treatment of pancreatic cancer does not increase the effectiveness of chemotherapy alone.

"Several hypotheses have been proposed to explain how antiangiogenic drugs enhance the treatment efficacy of cytotoxic chemotherapy, including impairing the ability of chemotherapy-responsive tumors to regrow after therapy," says author Dr. Yuval Shaked. Drs. Kerbel, Shaked, and colleagues had previously shown that treatment with a type of cytotoxic-like agent known as a vascular disrupting agent (VDA) induces rapid mobilization of cells called circulating endothelial progenitors (CEPs) from the bone marrow compartment that helps the tumor to regrow blood vessels and thereby recover from treatment.

The researchers built on this earlier observation by analyzing whether different, conventional chemotherapeutic drugs had variable abilities to impact CEP mobilization and whether antiangiogenic drugs could block chemotherapy-induced CEP responses and hence amplify their effectiveness. They found that paclitaxel rapidly induced CEP mobilization whereas gemcitabine did not. They went on to show that pharmacological inhibition of CEP mobilization by combination treatment with an antiangiogenic drug or treatment of mutant mice deficient in CEPs resulted in enhanced antitumor effects mediated by paclitaxel but not gemcitabine.

"Our results provide a new perspective regarding the impact that conventional chemotherapy can have on tumor angiogenesis and hence how combination with antiangiogenic drugs may amplify the antitumor effects of chemotherapy," explains Dr. Kerbel. "Further, our findings provide a potential explanation of why not all chemotherapy drugs will necessarily have their efficacy enhanced by the addition of an antiangiogenic agent when the mechanism involves blunting CEP mobilization acutely induced by the chemotherapy drug."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
2. New review suggests caution on drugs to raise good cholesterol
3. Can cancer drugs combine forces?
4. Study provides hope that some transplant patients could live free of antirejection drugs
5. Study provides hope that some transplant patients could live free of anti-rejection drugs
6. RA Drugs Linked to Slight Skin Cancer Risk
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Rock N Roll: Sex, Drugs and an Early Exit
9. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... , ... “A Respectful Response To Atheist Manifesto”: theological refutation ... is the creation of published author Richard Hostetter, a former missionary in Africa ... graduate degrees from Kent State University and the University of Ghana. , Published ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... publication of the first issue of its companion print magazine. The new magazine, ... cosmetic surgery thanks to information provided by board-certified doctors from across the country. ...
(Date:3/22/2017)... ... ... Old School Labs™, makers of the best-selling Vintage line of natural sports ... who trained with Floyd Mayweather, made his professional debut in London in 2003 and ... number of wins in contests in Britain, Germany and the U.S. , “We ...
(Date:3/22/2017)... ... March 22, 2017 , ... Influence Health, the ... solutions have enabled Children’s Hospital of The King’s Daughters (CHKD) to achieve a ... value of a digital marketing approach, the 206-bed pediatric teaching hospital in Norfolk, ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... research collaboration to translate advances in basic neuroscience at the BMRI labs into ... collaboration seeks to improve movement, vision, and cognition impaired by stroke, traumatic brain ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Insight 2022" drug pipelines to their offering. ... Global Immune ... gives comprehensive insight on clinical and non-clinical aspects involved in ... main streamline drugs in the immunotherapy treatment. Report helps to ...
(Date:3/22/2017)... Mar 22, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their ... The ... of around 7.1% over the next decade to reach approximately $129.81 ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 22, 2017  Applied BioMath ( ... to drug research and development, today announced the ... QSP Day 2017 is a day full of ... systems pharmacology (QSP) community. The focus is to ... de-risking and accelerating drug research and development. ...
Breaking Medicine Technology: